ClinicalTrials.gg
TerminatedNCT02023047Updated Nov 17, 2015

An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing

A Phase 1/2 interventional study of Nifedipine 12 mg coated suppositories in Anal Fissure, sponsored by RDD Pharma Ltd. Terminated at 4 sites in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-17.

Sponsored by RDD Pharma Ltd · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Met primary endpoint

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open label study. The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2). Approximately 30 subjects will participate into this 8-week study. The primary objective is to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and healing.

Read the detailed description

This is an open label study. The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2). Approximately 30 subjects will participate into this 8-week study. A screening visit will be used to determine subject suitability for inclusion in the trial. Within one week of the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will receive Coated Nifedipine 12 mg Suppository X2 a day (BID) (24 mg/day total) OR Coated Nifedipine 12 mg Suppository X1 a day (OD) (12 mg/day total) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication will be administered BID (in the morning and in the evening) or OD (only in the morning). In addition to receiving study medication, subjects will be maintained on a standard treatment for Anal Fissure: sitz baths, high fiber diet.

02

Conditions studied

  • Anal Fissure

Browse trials for

Keywords

  • Anal Fissure
  • Nifedipine
03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's enrollment of 33 is below the median of 99 across 65 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

RDD Pharma Ltd is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Single anal fissure
  • Signed written ;
  • Male or female subjects 18 to 65 years of age;
  • Has chronic anal fissure defined as history of anal pain at least three days a week for 30 days duration or more
  • Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present.
  • VAS of > 35 mm in screening visit
  • If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of (hysterectomy or tubal ligation at least 6 months prior to entry to the study or for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice appropriate (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone.
  • Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome.
  • Anal abscess
  • Fixed anal stenosis
  • Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, /stroke, arrhythmia, moderate to severe congestive heart failure, or cardiac valve abnormalities;
  • Type 1 diabetes mellitus;
  • Insulin treated type 2 diabetes mellitus;
  • History of Renal insufficiency.
  • History of Liver insufficiency.
  • Malignant disease within 5 years of screening;
  • Has uncontrolled hypertension (sitting blood pressure \<160/95 mmHg at screening)
  • History of chronic gastrointestinal disease.
  • History of rectal surgery.
  • History of gastrointestinal surgery.
  • History of , , .
  • In need of chronic use of medication, with the exception of medications.
  • Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure).
  • Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.
  • Is using drug that may affect rectal tone:
  • Calcium Channel Blocker such as:

    • Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)
    • Amlodipine (Amlow, Norvasc, Amlodipine-Teva)
    • Lercadipine (Vasodip)
    • Verapamil (Ikacor, Ikapress, Verapress)
    • Felodipine (Penedil)
    • Diltiazem (Adizem, Dilatam)
  • Nitrate donors such as:

    • Glyceryl Trinitrate (Deponit)
    • Isosorbid dinitrate (Isoket, Isolong)
    • Isosrbid mononitrate (Monocord, Monolong, Mononit)
    • Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual)
  • Has upon physical examination a rectal deformation or signs of rectal disease such as bleeding hemorrhoids, fistula. infection or space occupying lesion.
  • Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or
  • Is employed by RDD Pharma Ltd.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Once daily

    Nifedipine 12 mg Once daily

    Drug: Nifedipine 12 mg coated suppositories

  • Experimental
    Twice Daily

    Nifedipine 12 mg twice daily

    Drug: Nifedipine 12 mg coated suppositories

06

What researchers measure

Primary outcomes

  1. To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score

    Time frame: 8 weeks after study initiation

Secondary outcomes

  1. To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients .

    safety will be assessed by the number of participants with adverse events. Tolerability will be assessed by the number of participants that discontinue treatment.

    Time frame: 8 weeks

07

Study locations

4 sites
  • Macabi outpatient clinic
    Beer Sheba, Negev, Israel
  • Macabi outpatient clinic
    Rehovot, Israel
  • Macabi HMO outpatient clinic
    Tel Aviv, Israel
  • Asaf Harofe Hospital
    Zrifin, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2013
First posted
Dec 30, 2013
Start
Mar 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Nov 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02023047
Lead sponsor
RDD Pharma Ltd
Responsible party
Sponsor
First posted
Dec 30, 2013
Start date
Mar 2014
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Nov 17, 2015

Study contacts

Nir Barak, MD
study director · RDD Pharma Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion